Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03773107 · ClinicalTrials.gov registry record · Phase 1
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03773107 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 12 participants.
The verdict
NCT03773107, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.
Interventions
- DRUG Dexamethasone
- DRUG Ruxolitinib
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-01-03 |
| Est. Completion | 2024-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03773107
The ClinicalTrials.gov registry entry for NCT03773107 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03773107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03773107 about?
NCT03773107 is a clinical study titled "LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma". The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination tr...
What is the current status of trial NCT03773107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-01-03. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT03773107?
The interventions under investigation include: Dexamethasone (DRUG), Ruxolitinib (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT03773107?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.